evipedia.ai
← Back

Selank for Health & Longevity

Evidence Review created on 10/27/2026 using AI4L / Opus 5.5

Also known as: TP-7, Selank Acetate, Thr-Lys-Pro-Arg-Pro-Gly-Pro, TKPRPGP, Селанк

Motivation

Selank is a short synthetic peptide, a chain of seven amino acids built on a small fragment of the body’s own antibodies that helps activate immune cells. Developed by Russian research institutes and sold in Russia as nasal drops for anxiety and nervous exhaustion, it is promoted elsewhere as a calming compound that does not sedate. Its main proposed action is a gentle strengthening of the brain’s chief calming signal, together with slower breakdown of the body’s own calming peptides.

Interest outside Russia has grown with the spread of research peptides among people who manage stress and mental performance on their own. Most human studies were published in Russian journals by the teams that created the drug. In the United States it is sold online as a research chemical outside regulated pharmacy channels, which raises questions about what buyers actually receive.

This review examines the evidence on Selank for anxiety, mental fatigue and thinking, how it compares with conventional calming medications, its known and unknown risks, and how protocols are structured, framed for health-focused adults weighing it within a long-term longevity strategy.

Benefits - Risks - Protocol - Conclusion

This section lists overviews, commentary and key primary articles that discuss Selank in depth.

Only four items are listed: the remaining Selank content found was vendor marketing, encyclopedia entries or forum material, which this section excludes. None of the six priority experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, Lifespan.io) has published content on Selank that web and on-site searches could find; Selank is a niche Russian drug outside their usual coverage.

Grokipedia

Selank

An AI-written encyclopedia entry covering Selank’s development, chemistry, pharmacology, Russian dosing, human trials, user reports, legal status and comparison with Semax, a related Russian peptide; its claims need checking against primary studies.

Examine

No Examine article on Selank exists. Examine.com covers dietary supplements and does not typically cover pharmaceutical drugs or research peptides such as Selank.

ConsumerLab

No ConsumerLab article on Selank exists. ConsumerLab tests dietary supplements and does not typically cover pharmaceutical drugs or research peptides such as Selank.

Systematic Reviews

No systematic reviews or meta-analyses for Selank were found on PubMed as of October 26, 2026.

Mechanism of Action

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) joins tuftsin (an immune-activating fragment of immunoglobulin G, the most common antibody class; Najjar 1970) to a Pro-Gly-Pro tail that slows breakdown. Nearly all mechanistic work comes from its developer, the Institute of Molecular Genetics of the Russian Academy of Sciences, and partner institutes; the manufacturer Peptogen is registered at the Institute’s Kurchatov Square address (Russian Selank label, Kolomin 2014).

  • GABA-A modulation: In brain membranes Selank acted as a positive allosteric modulator (enhancing receptor response to its signal) of GABA-A receptors (the main calming receptors) and shifted GABA-related gene activity (Vyunova 2018, Volkova 2016).
  • Enkephalin protection: It inhibited enkephalinases (enzymes degrading enkephalins) in human serum, with an IC50 (concentration giving half-maximal inhibition) of 20 µM (Kost 2001).
  • Serotonin and BDNF: Rodent studies report increased serotonin turnover and higher BDNF (brain-derived neurotrophic factor, a protein supporting neuron growth) in the hippocampus (a memory region) (Semenova 2009, Inozemtseva 2008).

Competing view: each mechanism rests on single-laboratory assays at concentrations unconfirmed in the human brain; an independent review calls Selank poorly studied (Doyno 2021).

Pharmacology: 92.8% of an intranasal dose reaches the bloodstream; plasma levels fall within 5–5.5 minutes and the peptide reaches brain tissue (Russian Selank label). Peptidases (protein-cutting enzymes), with no reported cytochrome P450 liver-enzyme role, split it into fragments such as TKPRP and TKP (one-letter amino-acid codes) that may stay active (Zolotarev 2006). It showed negligible binding at dopamine D2 and delta- and mu-opioid receptors (subtypes of the dopamine and morphine receptors) (Meshavkin 2006).

Historical Context & Evolution

Tuftsin (Thr-Lys-Pro-Arg) was identified in 1970 as an antibody fragment that stimulates phagocytosis (immune cells engulfing microbes) (Najjar 1970), but it breaks down quickly in blood. Russian groups at the Institute of Molecular Genetics and the Zakusov Institute of Pharmacology appended the stabilizing glyproline (proline-glycine peptide) sequence Pro-Gly-Pro and, by the early 2000s, reported that the resulting heptapeptide reduced stress-induced behavior in rodents, shifting its profile from immune stimulant to anxiolytic (anxiety-reducing) (Kozlovskaya 2003).

The intended use was a non-sedating alternative to benzodiazepines (a class of sedating anti-anxiety drugs such as diazepam). Developer-linked comparative trials reported anxiety relief similar to medazepam (Zozulia 2008) and pronounced relief in a comparison with phenazepam (Medvedev 2014), and Selank was registered in Russia as non-prescription 0.15% nasal drops for anxiety, neurasthenia (chronic mental fatigue with irritability) and stress disorders (Russian Selank label).

Health-optimization interest came later, through the nootropic (cognition-enhancing) and research-peptide market, where Selank is valued as calming without dulling thought. Belgian regulators identified it in seized unlicensed preparations (Vanhee 2020), and the FDA (U.S. Food and Drug Administration) had placed it among compounding substances that may present significant safety risks before its nomination was withdrawn (FDA bulk drug safety-risk list). What changed was not new contrary trial evidence but scrutiny of the original evidence: a Russian review attributes the lack of international recognition to delayed adoption of good-clinical-practice standards (Deigin 2022). The developers’ findings have been neither independently confirmed nor refuted.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the controlled human trials are small active-comparator studies from one developer-linked Moscow research network, with no placebo arm and no independent replication.

Medium 🟩 🟩

Reduction of Anxiety Symptoms

In 62 adults with GAD (generalized anxiety disorder) or neurasthenia, Selank reduced anxiety on the Hamilton and Zung rating scales and the CGI (Clinical Global Impression) scale to a degree similar to the benzodiazepine medazepam (Zozulia 2008). A 60-patient comparison with phenazepam reported pronounced anxiety relief lasting a week after the last dose (Medvedev 2014). Both trials share developer co-authors and lack placebo arms, so spontaneous improvement cannot be excluded. No data exist for health-focused adults without an anxiety diagnosis.

Magnitude: Direction only: anxiety ratings fell with Selank to a degree similar to medazepam in adults with GAD or neurasthenia; the literature reports no outcome figure in its English-language abstracts.

Relief of Fatigue and Low Drive (Asthenia)

Asthenia (persistent mental and physical fatigue with low drive) is a core feature of neurasthenia. In the 62-patient trial, Selank showed antiasthenic and mild stimulant effects that medazepam did not (Zozulia 2008). The evidence comes from one trial in patients with anxiety disorders, not from healthy adults.

Magnitude: Direction only: fatigue and low-drive symptoms improved with Selank but not with medazepam in adults with GAD or neurasthenia; the literature reports no outcome figure in its English-language abstract.

Low 🟩

Fewer Benzodiazepine Side Effects When Added to Phenazepam

In an RCT (randomized controlled trial) of anxiety, hypochondriac (health-anxiety) and somatoform (unexplained physical symptom) disorders, 40 patients on Selank plus phenazepam had less sedation, memory impairment, sexual dysfunction and orthostatism (dizziness on standing) than 30 on phenazepam alone (Medvedev 2015). Evidence is indirect: Selank was tested only with phenazepam.

Magnitude: Direction only: fewer side effects on the UKU scale (a standard side-effect rating) with Selank plus phenazepam than with phenazepam alone; the literature reports no outcome figure in its English-language abstract.

Mild Cognitive Enhancement

A “mild nootropic” (thinking-enhancing) effect was reported in 60 anxious patients in the comparison with phenazepam (Medvedev 2014). The abstract names no test and gives no between-group result, so the finding is effectively uncontrolled; participants had anxiety disorders, not healthy adults.

Magnitude: Direction only: cognitive function improved in anxious patients taking Selank; the literature reports no outcome figure and names no test in its English-language abstract.

Speculative 🟨

Immune and Antiviral Effects

Selank shifted the Th1/Th2 cytokine balance (immune messengers of two arms of immune signaling) in anxious patients, an unvalidated marker, and protected mice against influenza (Uchakina 2008, Ershov 2009). Basis: biomarker and animal data only.

Antidepressant-Like Effects

Selank reduced depression-like behavior, such as immobility and loss of sugar preference, in rats and mice (Sarkisova 2008). The basis is animal data only; no human depression trial exists.

Protection of Memory Under Brain Stress

Selank raised hippocampal BDNF in rats and prevented alcohol-induced memory deficits (Inozemtseva 2008, Kolik 2019). The basis is animal data only; no human brain-aging data exist.

Easing Alcohol and Opioid Withdrawal

Single doses reduced anxiety in alcohol-withdrawn rats and lowered a morphine-withdrawal index by 39.6% (Kolik 2014, Konstantinopolsky 2022). The basis is animal data only.

Metabolic and Clotting Effects

In rats with experimental metabolic syndrome, Selank affected clotting, lipid and blood-sugar measures, and it showed anticoagulant (anti-clotting) activity in laboratory clotting tests (Mjasoedov 2014, Rogozinskaya 2017). The basis is animal and laboratory data only.

Improved Sleep in Anxiety States

The Russian label lists sleep disturbance among Selank’s registered indications (Russian Selank label), but no accessible trial reports a sleep outcome, and trials describe stimulant effects (Zozulia 2008). Basis: label claim only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No study has tested how gene variants alter response. In mice, only the high-anxiety BALB/c strain responded, suggesting that inherited stress reactivity shapes benefit (Vasil’eva 2016, Sokolov 2002).
  • Baseline biomarkers: Patients with GAD or neurasthenia had a shortened blood Leu-enkephalin half-life that tracked symptom severity; Selank lengthened it, mostly in GAD (Zozulia 2008). No commercial test measures this.
  • Sex: The English-language trial abstracts report no sex-specific results, and no sex difference in benefit is known.
  • Pre-existing conditions: Benefit data come from GAD, neurasthenia and phobic or somatoform disorders. Nasal congestion or heavy secretions reduce absorption (Russian Selank label).
  • Age: The label covers adults 18 and older (Russian Selank label); no trial reports outcomes in adults over 60, so benefit at the older end of the target range is unknown.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse-event information comes from the Russian product label and a few small active-comparator trials from one research network, with no replicated adverse-event data.

Medium 🟥 🟥

No risk reaches Medium: no controlled trial reports Selank adverse-event rates against a comparison group in an accessible report; human harm data are label statements and uncontrolled clinical-note records.

Low 🟥

Allergic Reactions, Including Delayed Reactions

The label lists allergic reactions, including delayed ones, at unknown frequency, partly attributed to the preservative methylparaben; its only other listed reaction is unpleasant taste when drops reach the throat (Russian Selank label). A review documents paraben allergenicity (Cashman 2005).

Magnitude: Not quantified in available studies. The label gives the frequency as unknown, and no study with a comparison group has reported an allergy rate.

Sedation, Dependence and Withdrawal ⚠️ Conflicted

An independent review groups Selank with GABA-acting sedatives whose abuse potential is unassessed (Doyno 2021). In an RCT, adding Selank reduced phenazepam’s sedation (Medvedev 2015), and the label reports no dependence or driving impairment (Russian Selank label). Net: trial data indicate low sedation risk; long-term dependence data are absent.

Magnitude: Direction only: sedation was lower with Selank plus phenazepam than with phenazepam alone (70 patients); the abstract reports no adverse-event rate for either group.

Harms From Unlicensed Products and Concurrent Peptide Use

Outside Russia Selank circulates as unlicensed powders and sprays (Vanhee 2020). Electronic health-record notes of Semax or Selank users, two-thirds also using other peptides, recorded isolated dyspnea (breathlessness), palpitations (a racing-heart sensation) and emergency visits during use (Marwaha 2026, preprint). Evidence is indirect: Semax and Selank users are pooled.

Magnitude: 27% (13 of 49) of confirmed Semax or Selank users had adverse-event or product-safety mentions in clinical notes (no control group).

Speculative 🟨

Immune Reactions to Compounded Products

The FDA states compounded Selank may, by certain routes, provoke immune reactions through aggregation and impurities, and that human safety information is lacking (FDA bulk drug safety-risk list). The basis is mechanistic only.

Bleeding Tendency

Selank was the most potent anticoagulant of three glyproline peptides in thromboelastography (a whole-blood clotting test) (Rogozinskaya 2017). The basis is laboratory data only; no human bleeding reports exist.

Effects on Fetal Brain Development

In mouse embryonic stem cells, Selank cut differentiation into GABA-producing neurons by 61%, though authors judged it non-toxic (Kobylyanskii 2017). The basis is cell data only.

Unknown Effects of Repeated Immune Modulation

Selank cut spleen activity of the complement gene C3 (part of innate immune defense) threefold within 30 minutes in mice (Kolomin 2014). Consequences of repeated courses are unknown; the basis is animal data only.

Risk-Modifying Factors

  • Genetic polymorphisms: No data exist on gene variants that alter risk. Clearance by widely distributed peptidases rather than polymorphic liver enzymes makes large metabolic differences unlikely, but this is untested.
  • Baseline biomarkers: No laboratory value is known to predict harm. People on warfarin with an unstable INR (international normalized ratio, a clotting-time measure) face an untested additive anticoagulant risk (Rogozinskaya 2017).
  • Sex: No sex-specific safety data exist; pregnancy and breastfeeding are label contraindications (Russian Selank label).
  • Pre-existing conditions: Paraben allergy, bleeding disorders and autoimmune disease (given immune effects in animals) are plausible modifiers; psychiatric conditions treated with several drugs add interaction uncertainty.
  • Age: No safety data exist for adults over 60. Older adults taking sedatives or anticoagulants carry greater interaction uncertainty, including fall risk if sedation adds up.

Key Interactions & Contraindications

Documented interactions:

  • Phenazepam (benzodiazepine): In a 70-patient trial, adding Selank reduced phenazepam’s sedation, memory impairment and asthenia, and improvement on the HDRS (Hamilton Depression Rating Scale) came earlier (Medvedev 2015). Consequence: fewer benzodiazepine side effects; sedation is still tracked when starting either drug.
  • Haloperidol, pentobarbital, hexobarbital, analeptics (the stimulant class that includes caffeine and nikethamide; no agent named), ethanol: No interaction found, according to the Russian label (Russian Selank label).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Other benzodiazepines (diazepam, alprazolam, clonazepam): Inferred from shared GABA-A modulation; Selank altered diazepam’s receptor effects in brain tissue (Vyunova 2018) and enhanced its anxiety-reducing effect in stressed rats (Kasian 2017). Possible additive calming; sedation is tracked during the first days.
  • Opioids and opioid blockers (morphine, oxycodone, naloxone, naltrexone): Inferred from enkephalinase inhibition; naloxone blocked Selank effects in mice (Meshavkin 2006). Possible additive opioid effects, or blunted Selank response with naltrexone.
  • Anticoagulants and antiplatelets (anti-clotting drugs: warfarin, apixaban, aspirin, clopidogrel): Inferred from anticoagulant activity in laboratory clotting tests (Rogozinskaya 2017). Possible increased bleeding; warfarin users can check INR after starting.
  • Serotonergic antidepressants (drugs raising serotonin signaling: sertraline, escitalopram, venlafaxine): Inferred from increased serotonin turnover in rats (Semenova 2009). Possible altered mood response or side effects; the prescriber reviews the combination.
  • Sedating over-the-counter antihistamines (allergy drugs) and sleep aids (diphenhydramine, doxylamine): Inferred from additive calming through GABA-A modulation. Possible excess drowsiness and impaired driving until the combined effect is known.
  • Over-the-counter nasal decongestants and steroid sprays (oxymetazoline, fluticasone): Inferred from altered nasal mucosa and absorption. Possible reduced Selank uptake; spacing the two by 15–30 minutes limits this.
  • Calming supplements (kava, valerian, phenibut, L-Theanine): Inferred from additive GABA-related calming; phenibut adds its own dependence risk, per a review (Doyno 2021). Possible excess sedation; adding one at a time limits this.
  • Supplements with antiplatelet effects (fish oil, ginkgo, high-dose vitamin E): Inferred from additive anticoagulant activity (Rogozinskaya 2017). Possible increased bruising or bleeding, relevant before surgery.
  • Semax and other peptides (CJC-1295, ipamorelin): Semax also inhibits enkephalinases (Kost 2001); concurrent use of several peptides is common among users (Marwaha 2026). Possible additive or unpredictable effects that cannot be attributed; starting one peptide at a time allows attribution.
  • Immunosuppressants (drugs that dampen immune activity: tacrolimus, methotrexate): Inferred from cytokine modulation (Uchakina 2008). Possible interference with immune control; the treating specialist reviews the combination.
  • Anesthesia and procedural sedation (propofol, midazolam): Inferred from additive GABA-A modulation. Possible deeper sedation; disclosing use and pausing Selank before elective procedures reduce this.

Populations who should avoid Selank:

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Registered product over research powders: The licensed 0.15% drops have a defined concentration and manufacturer, avoiding the identity, contamination and dosing errors of unlicensed preparations (Vanhee 2020).
  • Intranasal rather than injected use: Avoids injection-site infection and stays with the registered product’s route; the FDA’s immune-reaction warning for compounded Selank covers unnamed routes, so it may still apply (FDA bulk drug safety-risk list).
  • Labeled course length: 14-day courses with 1–3 week breaks (Russian Selank label) limit exposure to the unknown long-term immune and dependence risks.
  • Single-drop first dose: One drop per nostril on day 1, watching 24–48 hours for hives, swelling or breathing difficulty, screens for allergic and delayed allergic reactions; protocols stop use at any sign.
  • One new agent at a time: Starting Selank alone, without other peptides, lets any adverse event be attributed; among documented users, frequent concurrent peptide use prevented attributing reported effects to Selank (Marwaha 2026).
  • INR check on warfarin: INR before starting and 1–2 weeks after reduces the theoretical bleeding risk; an INR outside the individual’s target range is reported to the prescriber.
  • Caution with sedatives: Avoiding driving until the combined response to benzodiazepines, sleep aids or alcohol is known prevents accidents from additive sedation and falls.
  • Pregnancy test: A negative test before each course in women who could conceive avoids fetal exposure to an untested drug.

Therapeutic Protocol

Parameters other than cited doses (timing, cycling, titration) reflect common practice.

  • Registered regimen: 2 drops of the 0.15% (1.5 mg/mL) solution in each nostril three times daily for 14 days, repeatable after 1–3 weeks, as set by the developer-affiliated manufacturer (Russian Selank label).
  • Research-peptide approach: Users typically apply nasal sprays, and some inject subcutaneously; a psychiatrist notes no safe or effective dose is established for these products (Dr. Lewis blog). Doses are unstandardized.
  • Who popularized each approach: The Institute of Molecular Genetics and Zakusov Institute set the nasal-drop regimen; the biohacking community popularized research-peptide use, according to a psychiatrist’s review (Dr. Lewis blog).
  • Time of day: Morning to early afternoon, because stimulant effects were reported (Zozulia 2008) and some users find late doses disturb sleep (Dr. Lewis blog).
  • Half-life: Plasma levels fall within 5–5.5 minutes (Russian Selank label), yet effects outlast this, possibly through active fragments (Zolotarev 2006).
  • Single versus split dosing: The label splits the daily amount into three doses (Russian Selank label), matching rapid clearance.
  • Genetic polymorphisms: No variant is known to guide dose choice.
  • Sex: No sex-specific dosing exists; pregnancy excludes use.
  • Age: Adults only; older adults have no specific data, so the label dose is the usual starting point.
  • Baseline biomarkers: No laboratory marker guides dosing; higher baseline anxiety and fatigue scores defined the trial populations (Zozulia 2008).
  • Pre-existing conditions: Clearing nasal congestion improves absorption; in patients already on a benzodiazepine, add-on use has been studied (Medvedev 2015).

Discontinuation & Cycling

  • Short-term by design: The label frames Selank as 14-day courses (Russian Selank label); no human data cover continuous or lifelong use.
  • Withdrawal effects: The label states Selank causes no dependence (Russian Selank label), and anxiety relief persisted a week after the last dose (Medvedev 2014); no withdrawal syndrome has been reported.
  • Tapering: No taper is described for Selank. When Selank accompanies a benzodiazepine, that drug’s own withdrawal rules apply; in one trial Selank reduced phenazepam’s side effects after its withdrawal (Medvedev 2015).
  • Cycling: Courses repeat after 1–3 week breaks per the label (Russian Selank label); whether cycling preserves efficacy has not been tested, and tolerance has not been reported.

Sourcing and Quality

  • Registered pharmaceutical: Peptogen (Moscow) makes 0.15% nasal drops in 3 mL bottles with methylparaben; storage is 2–8 °C, and an opened bottle keeps 15 days at up to 25 °C (Russian Selank label).
  • Reputable brands: Peptogen is the only manufacturer of the registered drug; no Western brand holds independent third-party certification, and the FDA cites possible significant safety risks for compounded selank acetate, a withdrawn nomination (FDA bulk drug safety-risk list).
  • Research-chemical market: Online “research use only” vials and sprays are unregulated; Belgian regulators found Selank in seized unlicensed preparations (Vanhee 2020).
  • What to look for: A recent certificate of analysis from an independent laboratory showing identity by mass spectrometry, purity by HPLC (high-performance liquid chromatography, a purity test), and endotoxin (bacterial toxin residue) and sterility results for any injectable.
  • Analog substitution: Vendors also sell modified variants such as N-acetyl Selank amidate; PubMed contains no study of these variants, so trial data on Selank do not transfer.

Practical Considerations

  • Time to effect: Trial courses lasted 14 days (Uchakina 2008), and add-on Selank brought earlier improvement than phenazepam alone (Medvedev 2015); onset in healthy adults is unknown.
  • Common pitfalls: Treating research powders as equivalent to the registered drug, combining several peptides at once, dosing late in the day, expecting benzodiazepine-like sedation, and continuing indefinitely without breaks.
  • Regulatory status: Registered in Russia as a non-prescription anxiolytic (Russian Selank label); in the United States, selank acetate was nominated for compounding, placed by the FDA in category 2 (possible significant safety risks), then withdrawn by its nominators (FDA bulk drug safety-risk list).
  • Cost and accessibility: Inexpensive in Russian pharmacies, but difficult to obtain elsewhere; outside Russia access is mainly through importation or unregulated vendors.
  • Language of the evidence: Most clinical reports are Russian-language with brief English abstracts, so methods and numerical results are hard to verify.

Interaction with Foundational Habits

  • Sleep: Mixed, indirect: the label lists sleep disturbance among indications (Russian Selank label), yet trials report stimulant effects (Zozulia 2008). Added to phenazepam, it reduced that drug’s excess sleep duration (Medvedev 2015). Morning dosing avoids possible insomnia.
  • Nutrition: None known: the intranasal peptide is unaffected by meals, and no nutrient depletion is reported. Rat metabolic-syndrome data hint at lipid and blood-sugar effects (Mjasoedov 2014); oral intake would be digested, so drops are not swallowed.
  • Exercise: None studied in humans; no blunting of training adaptation is reported. Selank raised hippocampal BDNF in rats (Inozemtseva 2008), a pathway exercise also activates, so a potentiating effect is possible but untested.
  • Stress management: Direct: Selank was designed as a stress-protective agent and reduced stress-induced behavior in rodents (Kozlovskaya 2003). No trial has combined it with meditation or cognitive behavioral therapy, so it complements rather than replaces these practices.

Monitoring Protocol & Defining Success

Before starting, a baseline record is established: a GAD-7 score (Generalized Anxiety Disorder 7-item questionnaire), self-rated sleep and daytime fatigue, and resting heart rate. Women who could conceive take a pregnancy test, and warfarin users obtain an INR. The label requires no laboratory test (Russian Selank label).

Ongoing monitoring follows a set cadence: at day 3, at day 14 (end of the first course), and before each repeat course; warfarin users add an INR 1–2 weeks after starting. Success is a meaningful fall in GAD-7 from the individual’s own baseline without drowsiness, sleep disruption or allergic symptoms. No change after two full courses indicates non-response, and rash, swelling, breathing difficulty or new palpitations end use.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
GAD-7 score No established target; track change from own baseline Expected to change: main efficacy marker Self-rated over 2 weeks; score bands of 5, 10 and 15 mark mild, moderate and severe anxiety (Spitzer 2006)
Resting heart rate 60–100 beats/min (standard reference range) Safety check: palpitations reported in users Measure seated after 5 minutes’ rest, same time of day
Pregnancy test (urine or serum hCG) Negative (standard reference range) Safety check: pregnancy stops use hCG: human chorionic gonadotropin, the pregnancy hormone; before each course in women who could conceive
INR (warfarin users only) 0.8–1.2 (standard reference range) Safety check: rise changes use On warfarin, compare with own pre-Selank INR and prescribed target; same laboratory; pair with prothrombin time

Qualitative markers:

  • Anxiety and worry in daily situations
  • Daytime energy and fatigue
  • Mental clarity and concentration
  • Sleep onset and quality
  • Daytime drowsiness
  • Nasal comfort and any allergic symptoms

Emerging Research

  • No registered clinical trials: ClinicalTrials.gov lists no Selank trial as of October 2026, so no NCT ID (registry number) exists and no ongoing trial can change the conclusion soon.
  • Placebo-controlled replication: The only controlled clinical-outcome data are active-comparator trials (Zozulia 2008, Medvedev 2014). An independent placebo-controlled trial could strengthen the anxiety case or reveal that improvement reflected expectation and natural recovery.
  • Real-world safety surveillance: Health-record documentation of Selank use rose about 16% per quarter (Marwaha 2026); systematic adverse-event reporting could confirm low harm or uncover signals masked by concurrent peptide use.
  • Abuse-potential testing: Reviewers call for evaluation of abuse potential for GABA-acting agents, including Selank (Doyno 2021); results could weaken or strengthen its non-addictive reputation.
  • Brain imaging in healthy people: Single doses altered connectivity of the amygdala (threat-processing region) on fMRI (functional magnetic resonance imaging) in a placebo-controlled study of 52 healthy volunteers given Selank, Semax or placebo (Panikratova 2020); linking such changes to measured stress resilience would test relevance for healthy adults.
  • Addiction and withdrawal: Rat data on alcohol and morphine withdrawal (Konstantinopolsky 2022) await human trials, which could open a new indication or show no effect.

Conclusion

Selank is a seven-amino-acid peptide derived from an immune fragment, registered in Russia as a non-prescription nasal drop for anxiety and nervous exhaustion and sold elsewhere through an unregulated research-peptide market. For health-focused adults, its appeal is calm without sedation, mental dulling or dependence.

The best human evidence comes from small Russian trials in people with anxiety disorders. They suggest anxiety relief comparable to older sedating anti-anxiety drugs, less fatigue, and fewer side effects when Selank is added to such a drug. Cognitive, sleep, immune, antidepressant, brain-protective and withdrawal benefits rest on weaker or animal evidence, and no data address lifespan, healthy aging or people without an anxiety diagnosis.

Reported harms are few: allergic reactions, partly from a preservative, an unpleasant taste, and isolated breathlessness, a racing heart and emergency visits among users of unlicensed products. This short safety list reflects limited study rather than proven safety. Longer-term immune effects, use in pregnancy, interactions with anti-clotting and calming drugs, and the quality of products sold outside Russia remain uncertain, and the U.S. drug regulator has flagged safety concerns for pharmacy-made versions.

The evidence base is thin and concentrated: nearly every study comes from the institutes that created Selank and the linked company that manufactures it, with no comparison of clinical outcomes against a dummy treatment and no confirmation by outside teams. That shared origin is the main conflict of interest. The findings are consistent and plausible, but they remain unconfirmed rather than disproven.

Top - Benefits - Risks - Protocol